Nurix Therapeutics opened higher at $16.39, compared with its previous close of $16.33. In the last trading session, the stock traded between $15.59 and $16.55. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Nurix Therapeutics is now worth
$ 47.17
Resulting in a loss of
$ 52.83 (52.83%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
90%
Hold
10%
Sell
0%
Markets Today
Today's Change
$-0.73 (-4.49%)
Day High
$16.55
Day Low
$15.59
Day Open
$16.39
Prev Close
$16.33
Volume
9,62,976
1W Return
-2.18%
1M Return
-29.59%
3M Return
-39.91%
6M Return
-4.20%
1Y Return
21.28%
Fundamentals
Market Cap ($ Mn)
1,704
PE Ratio
-
PB Ratio
6.75
PEG Ratio
-
ROE
-55.87%
ROCE
-53.77%
EPS (TTM)
$5.03
Investment Returns
1 Week
-2.18%
1 Month
-29.59%
3 Months
-39.91%
6 Months
-4.20%
9 Months
-3.19%
Financials
Quarterly
All values in $ Mn
44.1
May 25
7.9
Aug 25
13.6
Nov 25
6.3
Feb 26
9.0
May 26
673.1
Aug 26
Updates
4Nov
Wells Fargo lowers Nurix price target to $20, maintains equal-weight
HC Wainwright raises Nurix Therapeutics price target to $36
HC Wainwright & Co. maintains a Buy rating on Nurix Therapeutics. Price target raised from $34 to $36 by analyst Robert Burns. Rating remains unchanged despite the price target increase.
27 days ago
13Oct
Baird raises Nurix Therapeutics price target to $36, keeps Outperform
Baird maintained an Outperform rating on Nurix Therapeutics. Price target raised from $33 to $36 by analyst Joel Beatty. Rating status remains unchanged despite the higher valuation.
EPS of $4.73 beat consensus estimate of $3.98 by 18.84%. Total revenue of $673.1 million exceeded estimates by 63.57%. Net income swung to $549.8 million from a loss of $86.4 million in Q3FY25. Revenue growth driven by $653.2 million license fee from Roche collaboration. Cash position rose to $1.1 billion, extending runway into second half of 2029.
1mo ago
7Oct
Nurix enrolls first patient in bexobrutideg CLL study
First patient enrolled in cohort combining bexobrutideg with venetoclax. Initial cohort focuses on relapsed/refractory CLL with potential expansion to first-line. Strategy includes evaluation of bexobrutideg with selected antibodies in Roche portfolio.
1mo ago
5Oct
Nurix Therapeutics secures $10 million as Gilead extends oncology deal
Nurix received a $10 million fee for extending the research term with Gilead Sciences. The extension covers an undisclosed oncology program for an additional two years. Total potential payments for Nurix are up to $1.3 billion based on milestones. GS-6791, an oral IRAK4 degrader, is currently in Phase 1 clinical development.
